MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Arcoxia 90mg tablets (Organon Pharma (UK) Ltd).

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Arcoxia 90mg tablets (Organon Pharma (UK) Ltd).

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Arcoxia 90mg tablets (Organon Pharma (UK) Ltd).

Stability Notes

Protect from moisture. Protect from light.

Provenance

This compatibility recommendation is derived from Eucreas 50mg/1000mg tablets (Novartis Pharmaceuticals UK Ltd).

Stability Notes

Protect from moisture. Protect from light.

Provenance

This compatibility recommendation is derived from Eucreas 50mg/1000mg tablets (Novartis Pharmaceuticals UK Ltd).

Stability Notes

Protect from moisture. Protect from light.

Provenance

This compatibility recommendation is derived from Eucreas 50mg/850mg tablets (Novartis Pharmaceuticals UK Ltd).

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Eudemine 50mg tablets (RPH Pharmaceuticals AB).

Stability Notes

Store in airtight containers.

Provenance

This compatibility recommendation is derived from Isotard 40XL tablets (Kyowa Kirin Ltd), Modisal XL 40mg tablets (Ennogen Pharma Ltd) and Zemon 40 XL tablets (Kent Pharma (UK) Ltd).

Stability Notes

Store for up to 14 days in MCA.

Provenance

This compatibility recommendation is derived from Adcal-D3 chewable tablets tutti frutti (Kyowa Kirin International UK NewCo Ltd).

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Cyklokapron 500mg tablets (Viatris UK Healthcare Ltd).

Print this list

Medicines under this category are suitable for use inside MCAs, although this is likely to be an off-label use.
Medicines under this category can theoretically be used inside an MCA; however, mitigations may need to be considered.
Medicines under this category are not suitable for use inside MCAs.
We do not have stability information for these medicines and therefore cannot make a recommendation on suitability in an MCA.